ADA: Clinical Benefit With Alirocumab in T2D Plus Statin Therapy
Researchers presented data from the ODYSSEY DM Insulin and Dyslipidemia trials at ADA 2017.
ADA 77th Scientific Sessions 2017
Hypoglycemia Effectivey Managed With New Nasal Glucagon Device
Hypoglycemic episodes, moderate or severe, can effectively and efficiently be managed by nasal glucagon in adult patients with type 1 diabetes.
Extended-Release Naltrexone/Bupropion Efficacious for Weight Loss in Type 2 Diabetes
Two studies examined the effects of naltrexone/bupropion on weight loss, glycemic parameters, and cardiovascular risks in patients with type 2 diabetes.
Glycemic Control and Mortality Risk With Statins in Type 2 Diabetes
Patients with type 2 diabetes taking statins after insulin initiation had better glycemic control, but their risk for mortality was higher compared with patients who did not take statins.
Ertugliflozin Plus Metformin Improves Glycemic Control in Type 2 Diabetes
A randomized double-blind trial examined the safety and efficacy of ertugliflozin plus metformin for inadequately controlled type 2 diabetes.
Low-Carbohydrate vs Low-fat Diet Success In Patients With Prediabetes Differs According to Fasting Insulin Levels
Fasting plasma glucose, insulin, and insulin sensitivity levels were measured to determine their prognostic value as markers for long-term weight loss.
Maternal Type 2 and Gestational Diabetes Lead to Increased Asthma Risk for Offspring
Researchers examined the relationship between maternal diabetes and asthma risk in children.
Mental Health Screenings in Pediatric Patients With Type 1 Diabetes
Mental health and behavioral screenings should be routine part of care for pediatric patients with diabetes
Device-Supported vs Routine Titration in Type 2 Diabetes
More patients in the device-supported group achieved a fasting self-monitored plasma glucose target of 90 to 130 mg/dL at week 16 without severe hypoglycemia.
Transition-of-Care Algorithm Performs Well in Surgery Patients With Type 2 Diabetes
HbA1c fell from 7.9%±2.0% at admission to 7.1%±1.5% at 3 months after discharge.
-
Loading...
-
Loading...
Want to read more?
Please login or register first to view this content.
Next post in ADA 77th Scientific Sessions 2017
